AMG 193 + docetaxel

AMG 193 + docetaxel is an investigational combination therapy consisting of AMG 193, a CNS-penetrant, MTA-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5), and docetaxel, an established chemotherapeutic agent. AMG 193 selectively induces synthetic lethality in solid tumors with homozygous methylthioadenosine phosphorylase (MTAP) deletion by inhibiting PRMT5, an enzyme essential for cellular methylation processes. Docetaxel is a taxane-based cytotoxic chemotherapeutic that inhibits microtubule depolymerization, leading to mitotic arrest and apoptosis. This combination is being studied in MTAP-deleted gastrointestinal, biliary tract, and pancreatic cancers to determine the safety profile and maximum tolerated dose, building on preclinical rationale that PRMT5 inhibition may sensitize MTAP-null tumor cells to cytotoxic agents like docetaxel[2][4].